Steven Kanner
Director Técnico/Científico/I+D en CARIBOU BIOSCIENCES, INC. .
Fortuna: 1 M $ al 30/04/2024
Cargos activos de Steven Kanner
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Director Técnico/Científico/I+D | 01/06/2017 | - |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Director/Miembro de la Junta | 10/10/2023 | - |
| Independent Dir/Board Member | 10/10/2023 | - |
Historial de carrera de Steven Kanner
Antiguos cargos conocidos de Steven Kanner.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 19/09/2013 | 01/06/2017 |
Formación de Steven Kanner.
| University of California, Berkeley | Undergraduate Degree |
| The University of Miami Leonard M. Miller School of Medicine | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 5 |
| Canadá | 2 |
Operativa
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
- Bolsa de valores
- Insiders
- Steven Kanner
- Experiencia
